Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 3 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Recs

1
Player Avatar crimfunk (75.38) Submitted: 2/2/2008 1:21:34 AM : Outperform Start Price: $4.38 VRX Score: +2,528.68

undervalued, EPS 5 Year Growth (%) 199.82

Featured Broker Partners


Advertisement